In other words, the high frequency of p53 signatures in fallopian tubes from all women, combined with the much higher risk of cancer in BRCA+ women, suggests that a germline BRCA mutation may serve as a promoter, enhancing the risk of transition from a p53 signature to malignancy [46]. The gene discussed is TP53; the disease is cancer.